Locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more ... line therapy for HER2+ metastatic gastric cancer, and recent data from the DESTINY ...

The drug is now cleared for use in adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low ...

Key HER2+ Gastric Cancer companies in the market include - Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer/Loxo Oncology, Eli Lilly and Company ...

NCT03615326), which included 698 patients with HER2-positive advanced gastric or GEJ adenocarcinoma not previously treated with systemic therapy for metastatic disease; 85% (n=594) of patients had ...

locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will ...

locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be ...